ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

Editors carefully fact-check all Drugwatch content for accuracy and quality.

Drugwatch has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

An Ohio Jury awarded thousands in damages to a hernia mesh patient and his wife in the latest federal bellwether trial against C.R. Bard and Becton Dickinson.

An April 2022 court filing shows Antonio Milanesi and his wife Alicia Morz De Milanesi were awarded $255,000, and $5,000 of the verdict was awarded for loss of consortium.

The verdict sends a clear message that Ventralex mesh is dangerous and defective, plaintiff’s lawyer Timothy O’Brien told Reuters in an email.

Milanesi had hernia repair surgery in 2007 with Bard’s Ventralex hernia repair mesh. His lawsuit claimed he had to undergo a second surgery in 2017 because the mesh was defective and caused a bowel abscess and infection.

This case was the second bellwether trial against Bard and a much-needed win for the plaintiffs. The first bellwether trial against Bard and Becton Dickinson took place in July 2021 and ended in a victory for the defendants.

The company maintains that its mesh products are safe.

Hernia mesh plaintiffs claim manufacturers designed and sold defective products that ended up harming patients. Bard and Becton Dickinson have the largest number of pending cases, but Johnson & Johnson’s Ethicon, Atrium and Covidien also have several thousand cases pending in federal multidistrict litigation.

Plaintiffs contend that defective mesh caused inflammation, pain, infections, perforated bowels and other problems that required additional surgery. Some patients have had to have more than one surgery to fix complications.

Part of the problem is polypropylene, a plastic used to make the mesh. Lawsuits say the material isn’t safe for implants because it degrades when implanted in the human body.

As of June 2022, Bard still faces 16,979 federal hernia mesh lawsuits in Ohio federal court. Becton Dickinson bought Bard in 2017, including responsibility for thousands of hernia mesh cases.

In addition to federal court cases, hernia mesh manufacturers face thousands more cases in state courts across the country.

So far, Atrium’s parent company, Getinge Group, has set aside about $66 million to settle more than 3,000 cases. Despite the offer to settle in December 2021, the company hasn’t admitted liability.

In addition to being made of polypropylene, Atrium’s meshes featured an Omega 3 fish oil coating. The coating was supposed to speed up healing and prevent mesh from sticking to internal organs, but lawsuits said the design backfired and contributed to complications.

The MDL against Ethicon is still ongoing and so far, there have been no trials. However, the company agreed to discuss settlement in May 2022. Details haven’t been disclosed.

We appreciate your feedback. One of our content team members will be in touch with you soon.

We appreciate your feedback. One of our content team members will be in touch with you soon.

Michelle Llamas has been writing articles and producing podcasts about drugs, medical devices and the FDA for nearly a decade. She focuses on various medical conditions, health policy, COVID-19, LGBTQ health, mental health and women’s health issues. Michelle collaborates with experts, including board-certified doctors, patients and advocates, to provide trusted health information to the public. Some of her qualifications include:

Drugwatch.com writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

Calling this number connects you with a Drugwatch representative. We will direct you to one of our trusted legal partners for a free case review.

Drugwatch's trusted legal partners support the organization's mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.

Join our newsletter to stay up to date on dangerous drugs and devices, keep up on lawsuit and settlement news, learn about FDA recalls, and more.

Keep people safe from potentially harmful drugs, medical devices and procedures by informing them of medical conditions, severe side effects and ways to take action.

This site complies with the HONcode standard for trustworthy health information: Verify here.

Drugwatch is located at: 1 South Orange Ave, Suite 201, Orlando, FL 32801

The information on this website is proprietary and protected. It is not a substitute for professional medical advice, diagnosis or treatment. Any unauthorized or illegal use, copying or dissemination will be prosecuted. Please read our disclaimer for more information about our website.

Drugwatch.com partners with law firms. This website and its content may be deemed attorney advertising. Prior results do not predict a similar outcome. For more information, visit our partners page.

© 2022 Drugwatch.com Privacy Policy / Advertising Disclosure / Do Not Sell My Info California Consumer Privacy Act (CCPA) Inquiries Drugwatch.com doesn’t believe in selling customer information. However, as required by the new California Consumer Privacy Act (CCPA), you may record your preference to view or remove your personal information by completing the form below. Request Type Please select a type:Information RequestData Deletion Full Name Full Name Phone Number Email Street Address Zip Code Submit

Drugwatch.com doesn’t believe in selling customer information. However, as required by the new California Consumer Privacy Act (CCPA), you may record your preference to view or remove your personal information by completing the form below.

Your web browser is no longer supported by Microsoft. Update your browser for more security, speed and compatibility.

If you would like to speak with a Drugwatch representative, please call 888-645-1617